<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00910754</url>
  </required_header>
  <id_info>
    <org_study_id>CR016942</org_study_id>
    <secondary_id>COU-AA-006</secondary_id>
    <nct_id>NCT00910754</nct_id>
  </id_info>
  <brief_title>A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A QT/QTc and Multi-dose PK Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration- Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of abiraterone acetate plus prednisone&#xD;
      on the conduction of electric charges within the heart and to determine the blood levels of&#xD;
      abiraterone acetate following administration in patients with metastatic castration-resistant&#xD;
      prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (identity of assigned study drugs will be known) study to evaluate the&#xD;
      effects of abiraterone acetate plus prednisone on the conduction of electric charges within&#xD;
      the heart in male patients diagnosed with metastatic castration-resistant prostate cancer (a&#xD;
      progressive form of prostate cancer that spreads to other parts of the body). At various time&#xD;
      points outline in the protocol from Day -1 of Cycle 1 up to Day 2 of Cycle 2, patients will&#xD;
      have electrocardiograms extracted from a 24 hour holter-monitor to evaluate the electrical&#xD;
      activity of their heart. Efficacy will be assessed according to Prostate Cancer Working Group&#xD;
      2 and modified Response Evaluation Criteria In Solid Tumors criteria. Serial blood samples&#xD;
      for pharmacokinetic analysis (how the drug concentrations change over time) will be collected&#xD;
      and safety will be monitored throughout the study. Patients will take 1000 mg of abiraterone&#xD;
      acetate once daily plus prednisone 5 mg twice daily orally (by mouth) until disease&#xD;
      progression and will be followed up for up to 60 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean maximal change in electrocardiogram QTc</measure>
    <time_frame>Baseline on Day -1 of Cycle 1 compared with Day 1 of Cycle 1, Cycle 2, Cycle 4 and every third cycle thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with change from baseline electrocardiogram QTc &gt;30 msec</measure>
    <time_frame>Pre-dose Cycles 1, 2, 4, and every third cycle after Cycle 4, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose, and end of study visit (4 weeks after last dose of study drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with change from baseline electrocardiogram QTc &gt;60 msec</measure>
    <time_frame>Pre-dose Cycles 1, 2, 4, and every third cycle after Cycle 4, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose, and end of study visit (4 weeks after last dose of study drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants affected by an adverse event</measure>
    <time_frame>Up to 30 days after the last dose of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with change in cortrosyn stimulation test</measure>
    <time_frame>Baseline and end of study visit (4 weeks after last dose of study drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with change in serum blood levels of testosterone</measure>
    <time_frame>Baseline and end of study visit (4 weeks after last dose of study drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with change in adrenocorticotropic hormone</measure>
    <time_frame>Baseline and end of study visit (4 weeks after last dose of study drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean plasma concentrations of abiraterone</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentrations of abiraterone</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum plasma concentration of abiraterone</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma-concentration-time curve from time 0 to the last quantifiable concentration of abiraterone</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma-concentration-time curve from time 0 to infinite time of abiraterone</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life of abiraterone</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression free survival</measure>
    <time_frame>Up to Month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to Month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with prostate specific antigen response</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to prostate specific antigen progression according to Prostate Cancer Working Group 2 criteria</measure>
    <time_frame>Up to Month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective radiographic response according to Prostate Cancer Working Group 2 criteria</measure>
    <time_frame>Up to Month 60</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Prostate Neoplasms</condition>
  <arm_group>
    <arm_group_label>Abiraterone acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take 1000 mg of abiraterone acetate once daily plus prednisone 5 mg twice daily orally (by mouth) until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone acetate</intervention_name>
    <description>Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.</description>
    <arm_group_label>Abiraterone acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 5 mg tablets administered orally twice daily.</description>
    <arm_group_label>Abiraterone acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate without&#xD;
             neuroendocrine differentiation or small cell histology&#xD;
&#xD;
          -  Documented metastatic disease&#xD;
&#xD;
          -  Has not received chemotherapy or has no more than one line of cytotoxic chemotherapy&#xD;
             or biologic therapy for treatment of castration resistant prostate cancer (CRPC)&#xD;
&#xD;
          -  Documented prostate specific antigen (PSA) progression as assessed by the investigator&#xD;
             according to Prostate Cancer Working Group 2 (PCWG2) criteria despite medical or&#xD;
             surgical castration, or prostate cancer progression documented by radiographic&#xD;
             progression according to Response Evaluation Criteria In Solid Tumors (RECIST)&#xD;
             criteria&#xD;
&#xD;
          -  Surgically or medically castrated with testosterone levels of &lt;50 ng/dL (&lt;2.0 nM)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of &lt;= 1&#xD;
&#xD;
          -  Agrees to protocol-defined use of effective contraception&#xD;
&#xD;
          -  Protocol-specified laboratory parameters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious or uncontrolled co-existent non-malignant disease, including active and&#xD;
             uncontrolled infection&#xD;
&#xD;
          -  Abnormal liver function&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Active or symptomatic viral hepatitis or chronic liver disease&#xD;
&#xD;
          -  Known brain metastasis&#xD;
&#xD;
          -  History of pituitary or adrenal dysfunction&#xD;
&#xD;
          -  Clinically significant heart disease as evidenced by myocardial infarction, or&#xD;
             arterial thrombotic events in the past 6 months, severe or unstable angina, or New&#xD;
             York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction&#xD;
             measurement of &lt; 50 % at baseline&#xD;
&#xD;
          -  Diagnosis of cardiac arrhythmia&#xD;
&#xD;
          -  Treatment with anti-arrhythmic drugs primarily for cardiac arrhythmia&#xD;
&#xD;
          -  Abnormal electrocardiogram&#xD;
&#xD;
          -  Other malignancy (except non-melanoma skin cancer, that is active or has a â‰¥ 30%&#xD;
             probability of recurrence within 24 months) History of gastrointestinal disorders&#xD;
             (medical disorders or extensive surgery) which may interfere with the absorption of&#xD;
             the study drug&#xD;
&#xD;
          -  Surgery or local prostatic intervention within 30 days of the first dose&#xD;
&#xD;
          -  Radiotherapy or immunotherapy within 30 days, or single fraction of palliative&#xD;
             radiotherapy within 14 days of administration of Cycle 1 Day 1&#xD;
&#xD;
          -  Any acute toxicities due to prior therapy that have not resolved to a NCI CTCAE&#xD;
             (version 3.0) grade of &lt;=1&#xD;
&#xD;
          -  More than one prior cytotoxic chemotherapy or biologic therapy for treatment of CRPC&#xD;
&#xD;
          -  Prior chemotherapy with mitoxantrone or other anthracyclines (ie, doxorubicin,&#xD;
             daunomycin, epirubicin and idarubicin)&#xD;
&#xD;
          -  Current enrollment in an investigational drug or device study or participation in such&#xD;
             a study within 30 days of Cycle 1 Day 1&#xD;
&#xD;
          -  Prior flutamide (Eulexin) treatment within 4 weeks of Cycle 1 Day 1&#xD;
&#xD;
          -  Prior bicalutamide (Casodex), nilutamide (Nilandron, Anandron) within 6 weeks of Cycle&#xD;
             1 Day 1&#xD;
&#xD;
          -  Previous abiraterone acetate or other investigational CYP17 inhibitor (eg, TAK-700)&#xD;
&#xD;
          -  Previous investigational antiandrogens (eg, MDV3100, BMS-641988)&#xD;
&#xD;
          -  Patients receiving anti-coagulant therapy&#xD;
&#xD;
          -  Condition or situation which, in the investigator's opinion, may put the patient at&#xD;
             significant risk, may confound the study results, or may interfere significantly with&#xD;
             patient's participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency-Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=2396&amp;filename=CR016942_CSR.pdf</url>
    <description>A QT/QTc and Multi-dose PK Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration- Resistant Prostate Cancer</description>
  </link>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>May 28, 2009</study_first_submitted>
  <study_first_submitted_qc>May 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2009</study_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate neoplasms</keyword>
  <keyword>Metastatic castration resistant prostate cancer</keyword>
  <keyword>Abiraterone acetate</keyword>
  <keyword>CB7630</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

